Boston Scientific introduces Precision pain reliever
This article was originally published in The Gray Sheet
Executive Summary
Spinal cord stimulation system for the treatment of chronic pain in the limbs, trunk and back will undergo a full European launch in 2006, with initial roll-out to begin this year. The firm received a CE mark for the device Sept. 13. Boston Scientific acquired the PMA-approved device with its $740 mil. purchase of Advanced Bionics in June 2004 and launched it in the U.S. in March. The European version includes a longer-life battery - not yet approved in the U.S. - that can last up to 25 years. Boston Scientific is developing several additional indications for Precision, including migraine headache (1"The Gray Sheet" Feb. 7, 2005, p. 4)...
You may also be interested in...
Advanced Bionics Spinal Cord Stimulation Launch Continues With Precision
Boston Scientific's Advanced Bionics unit expects to have a 100-person sales force in place by the end of the third quarter to market its Precision spinal cord stimulation (SCS) system for chronic pain and future indications, including migraine headache
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.